



Press release from Emotra AB (publ)
Göteborg, April 27, 2016

Bulletin from the Annual General Meeting of Emotra AB

The Annual General Meeting of shareholders in Emotra AB took place on April 26, 2016, at which the following important resolutions were made.

The income statement, balance sheet and proposed disposition of the Company's loss were adopted.

The Board of Directors and Chief Executive Officer were discharged from liability.

The Board members Margit Ferm, Lars-Håkan Thorell, Claes Holmberg and Roy Jonebrant were re-elected.

Thomas Nilsson, authorised public accountant at Ernst & Young AB, was re-elected as the Company's auditor. Markus Hellsten, authorised public accountant at Ernst & Young AB, was re-elected as deputy auditor.

Remuneration to the board was set at SEK 120,000, to be distributed among board members as the board sees fit.

Remuneration to the auditors as per the approved invoice.

For further information, please contact:

Claes Holmberg, CEO
Telephone: 0708-25 45 47
E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR™, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden
Tel: +46 708 25 45 47, www.emotra.se